Research

Research is central to the Queen's Neuroscience Institute's mission to be current on the latest treatments and to educate our providers and staff. We partner nationally with other institutions and researchers to bring expanded opportunities and the highest level of care to our patients.

Since its inception, the Neuroscience Institute has participated in more than 28 clinical trials in stroke, allowing over 155 patients from Hawaii to take part in national and international studies. We collaborate with other hospitals in the state to track stroke incidences and partner to deliver resources and options for patients. Queen's also maintains a comprehensive stroke database that monitors our methods and frequency of treating of strokes and other neurological conditions.

Our Comprehensive Epilepsy Center takes part in national trials in an effort to improve control of seizures and impact the quality of life for patients with epilepsy.

Other national and international studies in which we participate include research in traumatic brain injuries; devices; imaging; spinal cord surgery or injury; and examining physiology, treatment and outcomes to improve the rehabilitation and results for these patients.

A list of some of our current research can be found below.

If you have any questions regarding the clinical research at the Queen's Neuroscience Institute, please call 808-691-7175 or 808-691-4428.


CLINICAL TRIALS—STROKE

  • POINT: A randomized, double-blind, multicenter clinical trial to determine whether the combination of low-dose aspirin and clopidogrel increases the effectiveness in reducing the risk of stroke, heart attacks and other complications in patients who have just had a transient ischemic attack or a minor stroke. Principal Investigator: Dr. Rony Salem
  • RESPECT ESUS: A randomized, double-blind, multicenter clinical trial to test the safety and effectiveness of the anticoagulant, dabigatran etexilate (Pradaxa®), taken twice a day as compared to aspirin which is taken once a day for the prevention of another stroke in subjects with ESUS (Embolic Stroke of Undetermined Source). Principal Investigator: Dr. Rony Salem
  • QUEEN'S STROKE NAVIGATOR PROGRAM: Patient navigator programs, although readily used for cancer patients, have not been studied very much for stroke survivors. The purpose of this study is to test whether support after discharge, in the form of a stroke-specific patient navigation program has an impact on patient outcomes when compared to the current standard of care provided to stroke patients (both ischemic and hemorrhagic) at The Queen's Medical Center. Principal Investigator: Dr. Kazuma Nakagawa
  • MaRISS: A multi-center study trial designed to evaluate the long-term outcomes of stroke patients mild and rapidly improving symptoms. Principal Investigators: Dr. Cherylee Chang and Jennifer Moran, MS, APRN
  • STROKE DATABASE: A database through the Get With The Guidelines®-Stroke program and American Heart Association to collect clinical data of patients with acute stroke to support quality improvement in the treatment of acute stroke, and as part of our certification with The Joint Commission.

 
CLINICAL TRIALS—OTHER

  • STATUS (Epilepsy): A randomized, multi-center, placebo-controlled trial to evaluate the efficacy and safety of an investigational drug (IND) in the treatment of subjects with super-refractory status epilepticus. Principal Investigator: Dr. Cherylee Chang
  • Mechanisms of neurologic recovery: A study in Cardiopulmonary Arrest survivors using early electrophysiologic, MRI, and cognitive outcome measures. 

 

The information in this article is current as of January 2017 and will be periodically updated.